Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Cocaine-Related Disorders · Cocaine Dependence · DRUG

BRIGHT MINDS BIOSCIENCES

BRIGHT MINDS BIOSCIENCES INC.

BRIGHT MINDS BIOSCIENCES clinical programs — 1063 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
19 Vestry St, New York, NY 10013, US HQ
12 Employees
Public company Type
DRUG · NYSE Ticker
Company details
Status
Public
HQ
19 Vestry St, New York, NY 10013, US
Employees
12
Programs
1063
Drugs
444
Patents
57
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Clinical Programs

BRIGHT MINDS BIOSCIENCES projects

1,063 ClinicalTrials.gov programs sponsored by BRIGHT MINDS BIOSCIENCES.

BRIGHT MINDS BIOSCIENCES has 1,063 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

1,063 programs

Clinical programs

Page 5 of 23

  1. Bupropion and NRT

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    1 trial

  2. Buspirone

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  3. CAM2038

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule completed

    1 trial

  4. CDC-NCHSTP-4448

    BRIGHT MINDS BIOSCIENCES INC.

    Tuberculosis

    phase 2 small molecule completed

    1 trial

  5. CERC-501

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 small molecule completed

    1 trial

  6. CET/PT

    BRIGHT MINDS BIOSCIENCES INC.

    Schizophrenia

    phase 2 other completed

    1 trial

  7. CHRMS19-0129

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  8. CI-581aa

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid Dependence

    phase 2 small molecule completed

    1 trial

  9. CRAFT-T

    BRIGHT MINDS BIOSCIENCES INC.

    Heroin Dependence

    phase 2 other active

    1 trial

  10. CYB003

    BRIGHT MINDS BIOSCIENCES INC.

    Major Depressive Disorder

    phase 2 small molecule completed

    1 trial

  11. Caffeine 150 MG

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    1 trial

  12. Caffeine citrate

    BRIGHT MINDS BIOSCIENCES INC.

    Retinopathy of Prematurity

    phase 2 small molecule completed

    1 trial

  13. Candesartan with CBT

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule terminated

    1 trial

  14. Cannabidiol

    BRIGHT MINDS BIOSCIENCES INC.

    Radiculopathy

    phase 2 small molecule completed

    1 trial

  15. Cannabidiol (CBD) 600 mg

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-use Disorder

    phase 2 small molecule completed

    1 trial

  16. Cannabidiol - fsCBD

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule active

    1 trial

  17. Cannabis

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use

    phase 2 small molecule active

    2 trials

  18. Cariprazine Oral Capsule [Vraylar]

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorder

    phase 2 small molecule terminated

    1 trial

  19. Carvedilol

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  20. Ceremony

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use

    phase 2 other active

    1 trial

  21. Chantix

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule terminated

    2 trials

  22. Cigarettes with varying nicotine content

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  23. Citalopram

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    3 trials

  24. Clonazepam

    BRIGHT MINDS BIOSCIENCES INC.

    REM Sleep Behavior Disorder

    phase 2 small molecule completed

    1 trial

  25. Clonazepam

    BRIGHT MINDS BIOSCIENCES INC.

    Cannabis Use Disorder

    phase 2 small molecule completed

    1 trial

  26. Clonidine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule completed

    1 trial

  27. Cognitive Behavioral Intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  28. Cognitive Behavioral Therapy (CBT)

    BRIGHT MINDS BIOSCIENCES INC.

    Stress Disorders, Post Traumatic

    phase 2 other completed

    1 trial

  29. Combined intervention

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 other completed

    1 trial

  30. Community Reinforcement Approach (CRA) + HIV prevention

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  31. Computer-based Motivational Interviewing

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Abuse

    phase 2 other completed

    1 trial

  32. Computer-delivered brief intervention (5As)

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking

    phase 2 other completed

    1 trial

  33. Computerized cognitively stimulating activities

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  34. Computerized tasks

    BRIGHT MINDS BIOSCIENCES INC.

    Substance Use Disorders

    phase 2 other completed

    1 trial

  35. Contingency Management-Family Engagement (CM-FAM)

    BRIGHT MINDS BIOSCIENCES INC.

    Adolescent Substance Use

    phase 2 other completed

    1 trial

  36. Coreg

    BRIGHT MINDS BIOSCIENCES INC.

    Anxiety

    phase 2 small molecule terminated

    1 trial

  37. Cotinine fumarate

    BRIGHT MINDS BIOSCIENCES INC.

    Tobacco Use Disorder

    phase 2 small molecule completed

    2 trials

  38. Cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Opioid-Related Disorders

    phase 2 small molecule terminated

    1 trial

  39. D-Amphetamine 30mg

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  40. D-Cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Smoking Cessation

    phase 2 small molecule terminated

    1 trial

  41. D-Cycloserine (DCS)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use Disorders

    phase 2 small molecule completed

    1 trial

  42. D-cycloserine

    BRIGHT MINDS BIOSCIENCES INC.

    Substance-Related Disorders

    phase 2 small molecule terminated

    1 trial

  43. Decoy20

    BRIGHT MINDS BIOSCIENCES INC.

    Solid Tumor, Adult

    phase 2 small molecule active

    1 trial

  44. Desipramine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    3 trials

  45. Dextro-Amphetamine Sulfate

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    1 trial

  46. Dextroamphetamine

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine-Related Disorders

    phase 2 small molecule completed

    4 trials

  47. Disulfiram

    BRIGHT MINDS BIOSCIENCES INC.

    Alcohol-Related Disorders

    phase 2 small molecule completed

    1 trial

  48. Disulfiram

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Dependence

    phase 2 small molecule completed

    2 trials

Frequently asked questions

How many clinical projects does BRIGHT MINDS BIOSCIENCES have?

1,063 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.